PURPOSE: To investigate the utility of endorectal coil magenetic resonance imaging (eMRI) in predicting biochemical relapse in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy. METHODS AND MATERIALS: Between 2000 and 2008, 279 men with intermediate- or high-risk prostate cancer underwent eMRI of their prostate before receiving brachytherapy and supplemental intensity-modulated radiotherapy. Endorectal coil MRI was performed before treatment and retrospectively reviewed by two radiologists experienced in genitourinary MRI. Image-based variables, including tumor diameter, location, number of sextants involved, and the presence of extracapsular extension (ECE), were incorporated with other established clinical variables to predict biochemical control outcomes. The median follow-up was 49 months (range, 1-13 years). RESULTS: The 5-year biochemical relapse-free survival for the cohort was 92%. Clinical findings predicting recurrence on univariate analysis included Gleason score (hazard ratio [HR] 3.6, p = 0.001), PSA (HR 1.04, p = 0.005), and National Comprehensive Cancer Network risk group (HR 4.1, p = 0.002). Clinical T stage and the use of androgen deprivation therapy were not correlated with biochemical failure. Imaging findings on univariate analysis associated with relapse included ECE on MRI (HR 3.79, p = 0.003), tumor size (HR 2.58, p = 0.04), and T stage (HR 1.71, p = 0.004). On multivariate analysis incorporating both clinical and imaging findings, only ECE on MRI and Gleason score were independent predictors of recurrence. CONCLUSIONS: Pretreatment eMRI findings predict for biochemical recurrence in intermediate- and high-risk prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy. Gleason score and the presence of ECE on MRI were the only significant predictors of biochemical relapse in this group of patients.
PURPOSE: To investigate the utility of endorectal coil magenetic resonance imaging (eMRI) in predicting biochemical relapse in prostate cancerpatients treated with combination brachytherapy and external-beam radiotherapy. METHODS AND MATERIALS: Between 2000 and 2008, 279 men with intermediate- or high-risk prostate cancer underwent eMRI of their prostate before receiving brachytherapy and supplemental intensity-modulated radiotherapy. Endorectal coil MRI was performed before treatment and retrospectively reviewed by two radiologists experienced in genitourinary MRI. Image-based variables, including tumor diameter, location, number of sextants involved, and the presence of extracapsular extension (ECE), were incorporated with other established clinical variables to predict biochemical control outcomes. The median follow-up was 49 months (range, 1-13 years). RESULTS: The 5-year biochemical relapse-free survival for the cohort was 92%. Clinical findings predicting recurrence on univariate analysis included Gleason score (hazard ratio [HR] 3.6, p = 0.001), PSA (HR 1.04, p = 0.005), and National Comprehensive Cancer Network risk group (HR 4.1, p = 0.002). Clinical T stage and the use of androgen deprivation therapy were not correlated with biochemical failure. Imaging findings on univariate analysis associated with relapse included ECE on MRI (HR 3.79, p = 0.003), tumor size (HR 2.58, p = 0.04), and T stage (HR 1.71, p = 0.004). On multivariate analysis incorporating both clinical and imaging findings, only ECE on MRI and Gleason score were independent predictors of recurrence. CONCLUSIONS: Pretreatment eMRI findings predict for biochemical recurrence in intermediate- and high-risk prostate cancerpatients treated with combination brachytherapy and external-beam radiotherapy. Gleason score and the presence of ECE on MRI were the only significant predictors of biochemical relapse in this group of patients.
Authors: Matthew J Watson; Arvin K George; Mahir Maruf; Thomas P Frye; Akhil Muthigi; Michael Kongnyuy; Subin G Valayil; Peter A Pinto Journal: Future Oncol Date: 2016-07-12 Impact factor: 3.404
Authors: Maria A Gosein; Dylan Narinesingh; Shastri Motilal; Adrian P Ramkissoon; Cristal M Goetz; Kristy Sadho; Murrie D Mosodeen; Renee Banfield Journal: Radiol Imaging Cancer Date: 2020-07-31
Authors: Sung Yoon Park; Young Taik Oh; Dae Chul Jung; Nam Hoon Cho; Young Deuk Choi; Koon Ho Rha; Sung Joon Hong Journal: Eur Radiol Date: 2015-11-11 Impact factor: 5.315
Authors: Benedict Oerther; Moritz V Buren; Christina M Klein; Simon Kirste; Nils H Nicolay; Tanja Sprave; Simon Spohn; Deepa Darshini Gunashekar; Leonard Hagele; Lars Bielak; Michael Bock; Anca-L Grosu; Fabian Bamberg; Matthias Benndorf; Constantinos Zamboglou Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155
Authors: Cedric Panje; Thierry Panje; Paul Martin Putora; Suk-Kyum Kim; Sarah Haile; Daniel M Aebersold; Ludwig Plasswilm Journal: Radiat Oncol Date: 2015-02-22 Impact factor: 3.481
Authors: Alfonso Gomez-Iturriaga; Juanita Crook; Francisco Casquero; Claudia Carvajal; Arantxa Urresola; Begoña Canteli; Ana Ezquerro; Eduardo Hortelano; Jon Cacicedo; Jose Maria Espinosa; Fernando Perez; Pablo Minguez; Pedro Bilbao Journal: J Contemp Brachytherapy Date: 2014-06-09